181 related articles for article (PubMed ID: 23272972)
1. Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo.
Ucar DA; Magis AT; He DH; Lawrence NJ; Sebti SM; Kurenova E; Zajac-Kaye M; Zhang J; Hochwald SN
Anticancer Agents Med Chem; 2013 May; 13(4):595-602. PubMed ID: 23272972
[TBL] [Abstract][Full Text] [Related]
2. A novel small molecule inhibitor of FAK and IGF-1R protein interactions decreases growth of human esophageal carcinoma.
Ucar DA; Cox A; He DH; Ostrov DA; Kurenova E; Hochwald SN
Anticancer Agents Med Chem; 2011 Sep; 11(7):629-37. PubMed ID: 21707510
[TBL] [Abstract][Full Text] [Related]
3. Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth.
Ucar DA; Kurenova E; Garrett TJ; Cance WG; Nyberg C; Cox A; Massoll N; Ostrov DA; Lawrence N; Sebti SM; Zajac-Kaye M; Hochwald SN
Cell Cycle; 2012 Sep; 11(17):3250-9. PubMed ID: 22894899
[TBL] [Abstract][Full Text] [Related]
4. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells.
Liu W; Bloom DA; Cance WG; Kurenova EV; Golubovskaya VM; Hochwald SN
Carcinogenesis; 2008 Jun; 29(6):1096-107. PubMed ID: 18263593
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models.
Fukami S; Tomioka D; Murakami Y; Honda T; Hatakeyama S
BMC Res Notes; 2019 Jun; 12(1):347. PubMed ID: 31215459
[TBL] [Abstract][Full Text] [Related]
6. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.
Hochwald SN; Nyberg C; Zheng M; Zheng D; Wood C; Massoll NA; Magis A; Ostrov D; Cance WG; Golubovskaya VM
Cell Cycle; 2009 Aug; 8(15):2435-43. PubMed ID: 19571674
[TBL] [Abstract][Full Text] [Related]
7. Development of focal adhesion kinase inhibitors in cancer therapy.
Ma WW
Anticancer Agents Med Chem; 2011 Sep; 11(7):638-42. PubMed ID: 21787276
[TBL] [Abstract][Full Text] [Related]
8. The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.
Kurenova E; Liao J; He DH; Hunt D; Yemma M; Bshara W; Seshadri M; Cance WG
Oncotarget; 2013 Oct; 4(10):1632-46. PubMed ID: 24142503
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells.
Pathania D; Kuang Y; Sechi M; Neamati N
Br J Pharmacol; 2015 Jan; 172(1):50-63. PubMed ID: 25047070
[TBL] [Abstract][Full Text] [Related]
10. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
Zhang J; He DH; Zajac-Kaye M; Hochwald SN
Cell Cycle; 2014; 13(19):3143-9. PubMed ID: 25486573
[TBL] [Abstract][Full Text] [Related]
11. A small-molecule inhibitor, 5'-O-tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo.
Golubovskaya VM; Palma NL; Zheng M; Ho B; Magis A; Ostrov D; Cance WG
Anticancer Agents Med Chem; 2013 May; 13(4):532-45. PubMed ID: 22292771
[TBL] [Abstract][Full Text] [Related]
12. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.
Golubovskaya VM; Nyberg C; Zheng M; Kweh F; Magis A; Ostrov D; Cance WG
J Med Chem; 2008 Dec; 51(23):7405-16. PubMed ID: 18989950
[TBL] [Abstract][Full Text] [Related]
13. A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts.
Zheng D; Golubovskaya V; Kurenova E; Wood C; Massoll NA; Ostrov D; Cance WG; Hochwald SN
Mol Carcinog; 2010 Feb; 49(2):200-9. PubMed ID: 19885860
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.
Marlowe TA; Lenzo FL; Figel SA; Grapes AT; Cance WG
Mol Cancer Ther; 2016 Dec; 15(12):3028-3039. PubMed ID: 27638858
[TBL] [Abstract][Full Text] [Related]
15. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.
Liu TJ; LaFortune T; Honda T; Ohmori O; Hatakeyama S; Meyer T; Jackson D; de Groot J; Yung WK
Mol Cancer Ther; 2007 Apr; 6(4):1357-67. PubMed ID: 17431114
[TBL] [Abstract][Full Text] [Related]
17. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
[TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone targets the ATP-binding site of FAK, binds the FAK kinase domain and decreases FAK, Pyk-2, c-Src, and IGF-1R in vitro kinase activities.
Golubovskaya VM; Ho B; Zheng M; Magis A; Ostrov D; Cance WG
Anticancer Agents Med Chem; 2013 May; 13(4):546-54. PubMed ID: 22292772
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.
Stokes JB; Adair SJ; Slack-Davis JK; Walters DM; Tilghman RW; Hershey ED; Lowrey B; Thomas KS; Bouton AH; Hwang RF; Stelow EB; Parsons JT; Bauer TW
Mol Cancer Ther; 2011 Nov; 10(11):2135-45. PubMed ID: 21903606
[TBL] [Abstract][Full Text] [Related]
20. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
